Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
Want to see ARTL full AI Analyst Report?
Top Page
Artelo Biosciences
(NASDAQ:ARTL)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1.50
▲(20.97% Upside)
Action:Reiterated
Date:05/28/26
The score is driven primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn with financing dependence) and a clearly bearish technical setup (price far below key moving averages with negative momentum). Valuation offers limited support due to ongoing losses and no dividend data, while recent corporate actions increase dilution/funding risk.
Positive Factors
Specialized clinical-stage pipeline
Artelo’s focused R&D on the endocannabinoid system represents a clear strategic niche within neuroscience and inflammation therapeutics. This specialization concentrates scientific expertise, creates differentiated IP opportunities, and, if clinical progress continues, supports durable partner interest and out-licensing value beyond short-term market swings.
Negative Factors
No revenue; widening net losses
Artelo remains pre-revenue with a materially widening TTM net loss, underlining that operating deficits are not yet offset by commercial income. Over a multi-month horizon this creates sustained funding dependency and elevates dilution or partner-deal necessity risks if clinical progress does not materially de‑risk programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized clinical-stage pipeline
Artelo’s focused R&D on the endocannabinoid system represents a clear strategic niche within neuroscience and inflammation therapeutics. This specialization concentrates scientific expertise, creates differentiated IP opportunities, and, if clinical progress continues, supports durable partner interest and out-licensing value beyond short-term market swings.
Read all positive factors
Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.17M
Dividend YieldN/A
Average Volume (3M)89.20K
Price to Earnings (P/E)―
Beta (1Y)-0.83
Revenue GrowthN/A
EPS Growth27.77%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.23
Shares Outstanding2,333,540
10 Day Avg. Volume70,584
30 Day Avg. Volume89,202
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-1.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.84
Revenue Forecast (FY)N/A
Artelo Biosciences Business Overview & Revenue Model
Company Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled rece...
How the Company Makes Money
As a clinical-stage biotechnology company, Artelo Biosciences does not have a stable, product-based commercial revenue stream from marketed drugs (null for product sales revenue). The company primarily funds operations through financing activities...
Artelo Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
43
Neutral
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.78M | -12.54M | -10.11M | -9.93M | -10.08M | -7.44M |
| Net Income | -13.46M | -12.88M | -9.83M | -9.29M | -10.08M | -7.44M |
Balance Sheet | ||||||
| Total Assets | 12.52M | 2.80M | 4.70M | 13.04M | 20.42M | 12.63M |
| Cash, Cash Equivalents and Short-Term Investments | 10.27M | 600.00K | 2.34M | 10.43M | 17.53M | 10.06M |
| Total Debt | 755.00K | 693.00K | 104.00K | 23.00K | 63.00K | 95.00K |
| Total Liabilities | 5.85M | 4.07M | 1.84M | 1.29M | 1.02M | 593.00K |
| Stockholders Equity | 6.67M | -1.27M | 2.86M | 11.75M | 19.40M | 12.04M |
Cash Flow | ||||||
| Free Cash Flow | -8.11M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Operating Cash Flow | -8.11M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Investing Cash Flow | -62.00K | -62.00K | 7.77M | 3.51M | 2.96M | -3.44M |
| Financing Cash Flow | 17.73M | 6.87M | 112.00K | 567.00K | 0.00 | 14.11M |
Artelo Biosciences Technical Analysis
Negative
1.24
Price Trends
4.40
Negative
4.34
Negative
8.43
Negative
Market Momentum
-0.79
Negative
32.88
Neutral
26.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 4.40, and below the 200-day MA of 8.43, indicating a bearish trend. The MACD of -0.79 indicates Negative momentum. The RSI at 32.88 is Neutral, neither overbought nor oversold. The STOCH value of 26.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.
Artelo Biosciences Risk Analysis
Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artelo Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.51M | -0.59 | -209.36% | ― | ― | 87.76% | |
48 Neutral | $1.48M | -0.02 | -63.03% | ― | ― | 88.07% | |
42 Neutral | $143.82M | -0.17 | -1028.81% | ― | ― | 61.43% | |
41 Neutral | $7.88M | -0.43 | -262.78% | ― | ― | 82.92% | |
40 Underperform | $3.17M | -0.08 | 1937.42% | ― | ― | 27.77% |
* Healthcare Sector Average
ARTL
Artelo Biosciences
1.46
-16.81
-92.01%
BDRX
Biodexa Pharmaceuticals
3.36
-49.64
-93.66%
TOVX
Theriva Biologics
0.31
-0.14
-31.64%
INDP
Indaptus Therapeutics
1.44
-9.76
-87.14%
ENVB
Enveric Biosciences
2.32
-12.20
-84.02%
Artelo Biosciences Corporate Events
Legal ProceedingsPrivate Placements and Financing
Artelo Biosciences Launches Flexible At-The-Market Offering
Negative
May 27, 2026
On May 26, 2026, Artelo Biosciences, Inc. entered into an at-the-market equity offering agreement with H.C. Wainwright Co. to sell up to $6.53 million of its common stock from time to time on Nasdaq or other U.S. trading markets. Under the arrang...
Business Operations and StrategyPrivate Placements and Financing
Artelo Biosciences Ends ATM Offering, Shifts Financing Strategy
Neutral
May 15, 2026
On May 11, 2026, Artelo Biosciences, Inc. notified R.F. Lafferty Co., Inc. that it is terminating their at-the-market offering agreement, originally entered into on July 18, 2025, with the termination to become effective on May 18, 2026. Under th...
Business Operations and StrategyPrivate Placements and Financing
Artelo Biosciences Secures Bridge Financing Through Note Issuance
Negative
Mar 18, 2026
On March 12, 2026, Artelo Biosciences, Inc. entered into separate securities purchase agreements with Vanquish Funding Group Inc. and Boot Capital LLC, issuing 12% bridge notes with aggregate principal amounts of $237,300 and $113,000, respectivel...
Financial DisclosuresRegulatory Filings and ComplianceStock Split
Artelo Biosciences Enacts Reverse Stock Split Amid Strain
Negative
Mar 17, 2026
Artelo Biosciences executed a one-for-three reverse stock split of its common shares effective March 10, 2026, cutting its outstanding stock from 2,124,772 to about 708,323 shares and proportionally reducing authorized common and preferred share c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.